Access Erythropoietin (EPO), Catalog Number - A16364 a glycoprotein (~30,400 Daltons) produced primarily by the kidney, is the principal factor regulating red blood cell production (erythropoiesis) in mammals. Renal production of EPO is regulated by changes in oxygen availability. Under conditions of hypoxia, the level of EPO in the circulation increases and this leads to increased production of red blood cells.
Publicado el 12 de marzo de 2025 · Inicio del retiro: 3 de febrero de 2025
Resumen
FDA registra el retiro Z-1249-2025 de dispositivos médicos de Clase II, publicado el 12 de marzo de 2025 e iniciado el 3 de febrero de 2025. Empresa responsable: Beckman Coulter, Inc.; Estado: En curso; Cantidad reportada: 498 US; 1576 OUS; Lote: Catalog A16364 UDI-DI 15099590201838 Lot 439363. La Clase II indica posibles consecuencias temporales o médicamente reversibles, o una probabilidad remota de consecuencias graves.
Estado reportado al momento de publicación: Ongoing — openFDA actualiza semanalmente y este campo no refleja el estado más reciente. Confirma siempre con la fuente oficial.
Qué peligro representa
Affected lot (439363) exhibited a negative dose drop of -22% with native patient samples compared to alternate reagent lots. Patient samples tested with the affected lot may demonstrate repeatable falsely decreased results, which may lead to improper diagnosis or repeat testing.
Qué hacer
Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
Recibe un correo cuando FDA publique un retiro como este
Gratis. Solo te escribimos cuando hay un retiro nuevo que coincide. Te das de baja con un clic.
Detalles del retiro
- Fabricante
- Beckman Coulter, Inc.
- Distribuidor
- Domestic distribution to AL AR AZ CA CT FL ID IL IN KS MA MI NC NE NJ NY OH OR PA TN TX UT WA WV. International distribution to Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Czechia, Denmark, France, Germany, Hungary, India, Italy, Japan, Korea, Republic of, Netherlands, Philippines, Russian Federation, Saudi Arabia, Slovakia, Spain, United Kingdom of Great Britain and Northern Ireland
- Lote
- Catalog A16364 UDI-DI 15099590201838 Lot 439363
- Clasificación de riesgo
- Class II
- Área (FDA)
- device
- País
- United States
Retiros relacionados
- FDAROTOR ASSY-SW40, Reference Number 331302, when the rotors are installed in the following centrifuges: Optima28 de octubre de 2026
- FDAROTOR ASSY-SW41, Reference Number 331362, when the rotors are installed in the following centrifuges: Optima28 de octubre de 2026
- FDAIQ200 SPRINT, REF: 700-3322,700-3322RFB, 700-3325, 700-3326, B48997; IQ200 SELECT, REF: 700-3340, 700-3345,21 de octubre de 2026
- FDADxU 840m Iris, REF: C76947; DxU 850m Iris, REF: C4951321 de octubre de 2026
- FDAMedtronic Pipeline Vantage Embolization Device with Shield Technology, REF: PED3-021-350-16, PED3-021-250-14,12 de marzo de 2025
- FDABrand Name: TBS Osteo Product Name: TBS iNsight Model/Catalog Number: TBS iNsight v3.x / pn: OS-TBSi Software12 de marzo de 2025
Preguntas sobre este retiro
¿Access Erythropoietin (EPO), Catalog Number - A16364 a glycoprotein (~30,400 Daltons) produced primarily by the kidney, is the principal factor regulating red blood cell production (erythropoiesis) in mammals. Renal production of EPO is regulated by changes in oxygen availability. Under conditions of hypoxia, the level of EPO in the circulation increases and this leads to increased production of red blood cells. fue retirado del mercado?
Sí. FDA publicó el retiro Z-1249-2025 el 12 de marzo de 2025. Peligro reportado: Affected lot (439363) exhibited a negative dose drop of -22% with native patient samples compared to alternate reagent lots. Patient samples tested with the affected lot may demonstrate repeatable falsely decreased results, which may lead to improper diagnosis or repeat testing.
¿Qué debo hacer si tengo este producto?
Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit